Abstract Library

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#1420 A New Immunohistochemistry Prognostic Score (IPS) Based on MGMT, NDRG-1 and PHLDA-3 for Recurrence and Survival in Resected Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: In PanNET tumors contradictory data about the prognostic role of MGMT (O6-methylguanine DNA methyltransferase) has been published. NDRG-1 (N-myc downstream-regulated gen-1) and PHLDA-3 (Pleckstrin homology-like domain family A member 3) immunohistochemistry (IHC) expressions have been evaluated in several solid malignant tumors, but their roles in PanNET remain unknown

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Viudez A

Authors: Viudez A, Carvalho F, Maleki Z, Zahurak M, Laheru D,

Keywords: Pancreatic Neuroendocrine Tumor, MGMT, NDRG-1, PHLDA-3,